Scholarlink

Purpose <p>To evaluate outcomes of switching to aflibercept 8&#xa0;mg in eyes with neovascular age-related macular degeneration (nAMD) previously treated with anti-vascular endothelial growth factor (VEGF) agents.</p> Methods <p>This multicenter retrospective study examined 6-month treatment outcomes in eyes with nAMD previously treated and switched to aflibercept 8&#xa0;mg. Data including best-corrected visual acuity (BCVA), number of previous injections, and treatment intervals were collected. Central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and maximal pigment epithelial detachment (PED) height were measured on optical coherence tomography images.</p> Results <p>Analysis included 121 eyes (117 patients). Median number of previous anti-VEGF injections was 31.0 (interquartile range [IQR]: 20.5–55.5); median pre-switch interval was 5.0 (IQR: 4.0–8.0) weeks. At 6 months, 71 eyes (59%) continued aflibercept 8&#xa0;mg and 50 (41%) discontinued due to worsening at intervals ≥ 8 weeks. The discontinued group had significantly shorter pre-switch intervals (4.0 [IQR: 4.0–5.0] vs. 6.0 [IQR: 5.0–8.0], <i>P</i> &lt; 0.01) and thinner SFCT compared to the continued group (153 [IQR: 100–209] vs. 189 [IQR: 141–284], <i>P</i> = 0.012). At 6 months, CRT and PED decreased from 258 (IQR: 203–329) to 239 (IQR: 198–304) µm (<i>P</i> = 0.015) and from 195 (IQR: 112–293) to 164 (IQR: 82–263) µm (<i>P</i> = 0.007). BCVA was maintained (0.15 [IQR: 0.00–0.30] to 0.10 [IQR: 0.00–0.30]), <i>P =</i> 0.426). The median increase in injection interval was 2.0 (IQR: 1.0–3.5) weeks in continued eyes.</p> Conclusion <p>Switching to aflibercept 8&#xa0;mg may be an option to extend injection intervals, leading to a reduction in treatment burden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration

  • 期刊论文

  • 发表日期：

    2025年10月13日

查看全文
  • Keiko Kataoka,
  • Koji Tanaka,
  • Junichiro Honjyo,
  • Yasunori Miyara,
  • Nozomu Hashiya,
  • Yuto Watanabe,
  • Akiko Yamamoto,
  • Yu Wakatsuki,
  • Ayaka Nakai,
  • Ryo Mukai,
  • Yutaka Kato,
  • Nobuhiro Terao,
  • Marina Maehira,
  • Ichiro Maruko,
  • Moeko Kawai,
  • Tomohiro Iida,
  • Hideki Koizumi,
  • Tetsuju Sekiryu,
  • Ryusaburo Mori,
  • Annabelle A. Okada

摘要

Purpose

To evaluate outcomes of switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD) previously treated with anti-vascular endothelial growth factor (VEGF) agents.

Methods

This multicenter retrospective study examined 6-month treatment outcomes in eyes with nAMD previously treated and switched to aflibercept 8 mg. Data including best-corrected visual acuity (BCVA), number of previous injections, and treatment intervals were collected. Central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and maximal pigment epithelial detachment (PED) height were measured on optical coherence tomography images.

Results

Analysis included 121 eyes (117 patients). Median number of previous anti-VEGF injections was 31.0 (interquartile range [IQR]: 20.5–55.5); median pre-switch interval was 5.0 (IQR: 4.0–8.0) weeks. At 6 months, 71 eyes (59%) continued aflibercept 8 mg and 50 (41%) discontinued due to worsening at intervals ≥ 8 weeks. The discontinued group had significantly shorter pre-switch intervals (4.0 [IQR: 4.0–5.0] vs. 6.0 [IQR: 5.0–8.0], P < 0.01) and thinner SFCT compared to the continued group (153 [IQR: 100–209] vs. 189 [IQR: 141–284], P = 0.012). At 6 months, CRT and PED decreased from 258 (IQR: 203–329) to 239 (IQR: 198–304) µm (P = 0.015) and from 195 (IQR: 112–293) to 164 (IQR: 82–263) µm (P = 0.007). BCVA was maintained (0.15 [IQR: 0.00–0.30] to 0.10 [IQR: 0.00–0.30]), P = 0.426). The median increase in injection interval was 2.0 (IQR: 1.0–3.5) weeks in continued eyes.

Conclusion

Switching to aflibercept 8 mg may be an option to extend injection intervals, leading to a reduction in treatment burden.